Skip to main content
Midas Edge

IGC Pharma Inc

For the period ended Jun 30, 2024. Filed Aug 7, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 7, 2024

IGC$0.20+2.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Changes in Shareholder’s Equity

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’** EQUITY**

Number of Common SharesCommon Stock and Additional Paid in Capital ($)Accumulated Deficit ($)Accumulated Other Comprehensive Loss ($)Total Stockholders’ Equity ($)
Balances as of March 31, 202353,077118,965(100,665)(3,389)14,911
Common stock-based compensation & expenses, net-357--357
Issuance of common stock through offering (net of expenses)-----
Cancellation/forfeiture of shares-----
Common stock subscribed-----
Net loss--(2,075)-(2,075)
Foreign currency translation---99
Balances as of June 30, 202353,077119,322(102,740)(3,380)13,202
Balances as of March 31, 202466,691124,409(113,665)(3,423)7,321
Common stock-based compensation & expenses, net-433--433
Issuance of common stock through offering (net of expenses)8,9452,507--2,507
Cancellation/forfeiture of shares-----
Common stock subscribed-----
Net loss--(2,378)-(2,378)
Foreign currency translation---(3)(3)
Balances as of June 30, 202475,636127,349(116,043)(3,426)7,880

| June 30, 2024, Form 10-Q

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.